# A Comparison of Combivent UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg)

> **NCT00273962** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 500 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** ipratropium plus salbutamol UDV
- **DRUG:** salbutamol UDV

## Key facts

- **NCT ID:** NCT00273962
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2003-11
- **Final completion:** 2003-11
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2013-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00273962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00273962, "A Comparison of Combivent UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00273962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*